HALO News Alert Halozyme Therapeutics (HALO) 7.64 12/16/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Halozyme Therapeutics (HALO) 7.64 $HALO

United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 40.85 (-0.89), RTIX: 4.84 (-0.13), HALO: 7.64 (-0.03), EBS: 25.91 (+0.76), ANIK: 36.64 (+0.34), MDXG: 10.65 (-0.21)

Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 85.87 (-0.33), BIIB: 325.13 (-10.67), ACAD: 30.02 (-0.32), NBIX: 20.46 (-0.18), HALO: 7.64 (-0.03)

Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting
PR Newswire - Fri Dec 12, 7:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) today. The first of the presentations includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes additional supportive preclinical information on the utility of hyaluronan (HA) as a potential biomarker for cancer treatments. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme. PEGPH20 degrades the hyaluronan coating that may provide a supportive environment in many solid tumors.
HALO: 7.64 (-0.03)

Can Pfizer’s Cholesterol Drug Catch Up To The Competition?
Leo Sun, The Motley Fool - Motley Fool - Thu Dec 11, 6:28AM CST
Pfizer 's revenue has dramatically declined since 2011, the year Lipitor went off patent in the U.S. The blockbuster cholesterol drug, which already lost exclusivity in several markets at the time, still generated sales of $9.6 billion that year,...
HALO: 7.64 (-0.03), PFE: 30.67 (-0.19), AMGN: 159.44 (-0.16), SNY: 45.38 (+0.98), REGN: 396.13 (-4.88)

Halozyme Therapeutics - Buy The Drug Delivery Platform And Get A Cancer Drug For Free
Small Pharma Analyst - at Seeking Alpha - Tue Dec 09, 10:56AM CST

HALO: 7.64 (-0.03)

Halozyme Therapeutics To Present At The 25th Annual Oppenheimer Healthcare Conference
PR Newswire - Wed Dec 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York on Wednesday, December 10, 2014 at 1:00 p.m. ET/10:00 a.m. PT. David Ramsay, Vice President and Chief Financial Officer, will provide a corporate overview.
HALO: 7.64 (-0.03)

Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 25, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 1:00 p.m. EDT/10:00 a.m. PDT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 7.64 (-0.03)

Halozyme Therapeutics Earnings Review: 14 Days after Announcement Shares Down 8.6% (HALO)
Comtex SmarTrend(R) - Mon Nov 24, 9:18AM CST
When Halozyme Therapeutics (NASDAQ:HALO) reported earnings 14 days ago on November 10th, 2014, analysts, on average, expected the company to report a loss of $0.14 on sales of $16.5 million. Halozyme Therapeutics actually reported a loss of $0.16 per share on sales of $14.6 million, missing EPS estimates by $0.02 and missing revenue estimates by $1.9 million. Since the company's report, shares of Halozyme Therapeutics have fallen from $9.32 to $8.52, representing a loss of 8.6% in the past 14 days.
HALO: 7.64 (-0.03)

Halozyme Therapeutics Earnings Review: 7 Days after Announcement Shares Down 8.4% (HALO)
Comtex SmarTrend(R) - Mon Nov 17, 3:10PM CST
A week ago on November 10th, 2014 Halozyme Therapeutics (NASDAQ:HALO) reported earnings and analysts, on average, expected a loss of $0.14 on sales of $16.5 million. The company actually reported a loss of $0.16 per share on sales of $14.6 million, missing EPS estimates by $0.02 and missing revenue estimates by $1.9 million. Since the company's report, shares of Halozyme Therapeutics have fallen from $9.32 to $8.54, representing a loss of 8.4% in the past 7 days.
HALO: 7.64 (-0.03)

Halozyme Therapeutics (HALO) Stock Is Slipping Today on Weak Third Quarter Earnings
at The Street - Tue Nov 11, 10:42AM CST
Halozyme Therapeutics (HALO) stock is down after the company reported lower than expected third quarter earnings late Monday.
HALO: 7.64 (-0.03)

Halozyme net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 7:55AM CST

HALO: 7.64 (-0.03)

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:33PM CST

HALO: 7.64 (-0.03)

Halozyme Therapeutics meets 3Q profit forecasts
Automated Insights - Mon Nov 10, 5:51PM CST
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $20.3 million in its third quarter.
HALO: 7.64 (-0.03)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:36PM CST

DTSI: 30.03 (-0.41), W: 18.40 (-0.76), HALO: 7.64 (-0.03), MODN: 10.51 (+0.20), CALL: 7.62 (-0.03), LLNW: 2.77 (+0.05), KRG: 27.45 (unch), VSLR: 8.15 (-0.04), CMLS: 3.78 (-0.07), SSE: 5.10 (+0.31)

Halozyme Therapeutics misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:21PM CST

HALO: 7.64 (-0.03)

Halozyme Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:05PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2014. Financial highlights for the third quarter include revenues of $14.6 million and a net loss of $20.3 million, or $0.16 per share. This compares to revenues of $16.0 million and a net loss of $19.3 million, or $0.17 per share, for the third quarter of 2013.
HALO: 7.64 (-0.03)

Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST

HK: 1.76 (-0.04), WWD: 47.50 (+0.48), LLNW: 2.77 (+0.05), FXEN: 1.58 (+0.07), RMTI: 8.28 (+0.10), CZR: 12.16 (-0.13), EGY: 4.20 (+0.06), ICUI: 80.40 (+0.08), ICEL: 5.41 (+0.14), SAAS: 8.09 (unch), DMD: 6.23 (-0.13), NPSP: 30.47 (+0.39), SCLN: 8.17 (+0.28), ATHX: 1.23 (-0.04), CMLS: 3.78 (-0.07), TC: 1.45 (+0.03), ATW: 26.89 (+0.13), CLUB: 5.91 (-0.09), RAX: 45.33 (-0.40), PTLA: 27.37 (unch), IPAR: 26.58 (+1.26), ATLS: 25.41 (-0.33), AMBC: 22.46 (-0.05), CUI: 7.21 (-0.09), PDLI: 7.32 (-0.07), OMER: 20.51 (-0.62), PRAA: 57.37 (-0.62), CARA: 9.54 (-0.19), HALO: 7.64 (-0.03), MODN: 10.51 (+0.20), CALL: 7.62 (-0.03), ASEI: 48.93 (+1.85), HGR: 21.16 (-0.19), ERII: 4.65 (-0.07)

Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
PR Newswire - Wed Nov 05, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 12, 2014 at 4:00 p.m. ET/2:00 p.m. MT/1:00 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 7.64 (-0.03)

Halozyme to Host Third Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Nov 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2014 on Monday, November 10, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the third quarter 2014.
HALO: 7.64 (-0.03)

Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma
PR Newswire - Fri Oct 31, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
SNTA: 2.66 (+0.02), ACAD: 30.02 (-0.32), HALO: 7.64 (-0.03), ISIS: 54.94 (-1.99), NSPH: 0.37 (+0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 170

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 20

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 139

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 100

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 147

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 118

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 86

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 15

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 14

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

Furniture.com Launches $1,500 Giveaway for Back-to-School Fun

Updated Category News Views 154

Exciting Giveaway from Furniture.com Just in Time for School The online marketplace, Furniture.com, is inviting new social media followers to participate in an exciting giveaway allowing one lucky winner to receive a $1,500 gift card. This giveaway is perfect for anyone looking to enhance their living spaces, such as dorms, home offices, or children's rooms. Transforming...

Continue Reading
Kraken Robotics Achieves Unprecedented Growth in Q3 2025

Updated Category News Views 369

Kraken Robotics Inc. Reports Stellar Q3 2025 Results Kraken Robotics Inc. (TSXV: PNG, OTCQB: KRKNF) has recently released its financial results for Q3 2025, showcasing a remarkable growth trajectory. The company reported consolidated revenue of $31.3 million, marking a significant 60% increase from $19.6 million in the same quarter last year. This surge in revenue can be...

Continue Reading
NVIDIA Innovates AI for Robotics and Autonomous Solutions

Updated Category News Views 337

NVIDIA Enhances Robotics and Automation with New AI Models NVIDIA Corp (NASDAQ: NVDA) is making waves in the semiconductor landscape with its latest advancements in artificial intelligence (AI). With a staggering revenue exceeding $113 billion, NVIDIA has announced innovative generative AI models aimed at improving its Omniverse platform. This initiative is focused on...

Continue Reading
Takeda's ENTYVIO: Transforming IBD Treatment and Market Growth

Updated Category News Views 590

ENTYVIO's Impact on IBD Treatment Takeda Pharmaceutical continues to enhance patient care with ENTYVIO, a gut-selective biologic designed specifically for inflammatory bowel disease (IBD) management. With the recent introduction of a subcutaneous formulation, ENTYVIO has improved patient convenience, allowing for easier administration at home. This evolution in treatment...

Continue Reading
Join AM Best's Complimentary Webinar on AI Litigation Strategies

Updated Category News Views 43

AM Best Webinar Overview AM Best, a global leader in insurance credit ratings, is excited to announce a complementary webinar titled “Defending Artificial Intelligence Claims.” This informative session aims to delve into the intricate world of AI-related legal challenges. Key Discussion Points The webinar will take place at 2:00 p.m. (EST) and features a panel of...

Continue Reading